Liposomal iron dramatic effect on chronic kidney disease pediatric anemia: a randomized clinical trial

Abstract

BACKGROUND: Anemia affects pediatric quality of life. It can cause hypoxia and loss of concentration. There are a lot of iron supplements used in treating pediatric CKD-induced anemia our study aimed to evaluate the effectiveness of oral liposomal iron in treating pediatric CKD anemia compared tointravenous iron dextran. METHODS: This randomized, parallel study was conducted on 60 CKD pediatric patients. The patients were categorized into two groups. Group 1 comprises 30 pediatric patients administered oral liposomal iron 30 mg/day for 3 months. Group 2 comprises 30 pediatric patients administered intravenous iron dextran 50 mg three times/ week for 3 months. RESULTS: Both groups have no statistically significant difference in Hb, RBCS, MCV, PLTs, RDW-CV, Cr, Hepcidin, Ferritin, Iron, and Transferrin levels after 3 months of treatment. Liposomal iron has higher efficacy than IV dextran after 3 months of treatment since there is a significant difference within the group between before and after treatment period at Hb, RBCS, HCT, MCV, RDW-CV, Hepcidin, Ferritin, Iron, TIBC, and Transferrin levels with no reported side effects during the study period. CONCLUSION: Oral liposomal iron has higher efficacy than IV dextran, which is the traditional CKD anemia treatment in pediatric with no reported side effects. IMPACT: The key message of our article is to determine a safe, effective, easy to use, and less costly treatment of chronic kidney disease anemia in pediatrics. Our study will add to the existing literature a suggestion of an effective and safe treatment for pediatric chronic disorder, the traditional treatment has a lot of serious side effects. The impact of our study is to treat anemia resulted from chronic kidney disease in pediatrics with oral drug that has higher efficacy than the traditional injectable drug, this will lead to higher rate of anemia treatment due to higher rate of children compliance.